OrbiMed Israel BioFund GP Limited Partnership - Jul 28, 2021 Form 4 Insider Report for BiomX Inc. (PHGE)

Role: 10%+ Owner
Signature: OrbiMed Israel GP Ltd., by /s/ Carl L. Gordon
Stock symbol: PHGE
Transactions as of: Jul 28, 2021
Transactions value $: $0
Form type: 4
Date filed: 7/30/2021, 06:20 PM
Next filing: Mar 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHGE	Common Stock, $0.0001 par value	Purchase		+500K	+21.61%		2.81M	Jul 28, 2021	See Footnotes	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PHGE	Warrants (Right to Buy)	Purchase		+375K			375K	Jul 28, 2021	Common Stock	375K	$5.00	See Footnotes	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership ("OIP") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock. The purchase price of each unit was $4.00.
F2	The purchase reported on this Form 4 were made by OIP. Following the transactions reported on this Form 4, OIP LP is the direct owner of 2,172,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of OIP and OII. By virtue of these relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and OII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Nissim Darvish, Anat Naschitz, and Erez Chimovits.
F3	This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.